Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Inclusion Criteria: * Histologically confirmed diagnosis of resectable gastric adenocarcinoma or adenocarcinoma of the esophagogastric junction (type II and type III according to Siewerts classification) * Macroscopic peritoneal carcinomatosis (stage P1-4 according to Gilly et al., appendix 1) * Patients potentially eligible for gastrectomy after primary systemic (and intraperitoneal) treatment * Signed and dated informed consent before the start of specific protocol procedures * Age \> 18 years * ECOG Performance Status of 0 or 1 * Life expectancy of at least 12 weeks * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening * Hemoglobin \> 10.0 g/dl * Leukocyte count \> 4.000/μl; absolute neutrophil count (ANC) \> 2.000/μl * Platelet count \> = 100.000/µl * Total bilirubin \< 1,5 times the upper limit of normal * ALT and AST \< 3 x upper limit of normal * Alkaline phosphatase \< 5 x ULN * Serum creatinine \< 1.5 x upper limit of normal and creatinine clearance \> 60 ml/min * The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations Exclusion Criteria: * Distant metastasis other than peritoneal seedings * Prior diagnosis of any malignancy not cured by surgery alone less than 5 years before study entry * Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) = \< 1 year before enrolment * History of HIV infection or chronic hepatitis B or C * Active, clinically serious infections (\> grade 2 NCI-CTC version 3.0) * Pre-existing neuropathy \> grade 1 (NCI CTCAE), except for loss of tendon reflex * Patients with seizure disorder requiring medication (such as steroids or antiepileptics) * History of organ allograft * Patients undergoing renal dialysis * Known hypersensitivity to any of the drugs given in the study; known hypersensitivity to murine (rat and/or mouse) proteins * Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study * Excluded therapies and medications, previous and concomitant: * Prior anti-cancer chemotherapy or immunotherapy. * Investigational drug therapy outside of this trial during or within 4 weeks of study entry * Major surgery within 4 weeks of starting the study, and patients must have recovered from effects of major surgery * Pregnant or breast-feeding patients, or planning to become pregnant within 6 months after the end of treatment. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and for 6 months after the end of treatment * Substance abuse, medical, psychological or social conditions that may interfere with the patient's understanding of the informed consent procedure, participation in the study or evaluation of the study results